tiprankstipranks

Allan Shaw Insider Profile

4 Followers
Allan Shaw, Director at Akari Therapeutics, holds 0.00 shares in Onconetix (Ticker: ONCO), holds 33.53K shares in Akari Therapeutics (Ticker: AKTX), holds ― shares in CalciMedica (Ticker: CALC). Most recently, Allan Shaw Bought ― shares of Onconetix on Aug 23, 2022 for an estimated value of 296.36.
tipranks
Allan Shaw

Allan Shaw
Akari Therapeutics (AKTX)
Director

Ranked #33,491 out of 97,944 Corporate Insiders

Profitable Transactions

50%
1 out of 2 Profitable Transactions

Average Return

+36.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$91K
100.00%
0.00%
0.00%
A breakdown of Allan Shaw's holdings

Insider Roles

Akari Therapeutics
(AKTX)
Director
Onconetix
(ONCO)
Director
CalciMedica
(CALC)
Director
Roles that Allan Shaw holds in companies

Most Profitable Insider Trade

Stock:
Onconetix
(ONCO)
Rating:Informative Sell
Date:Aug 23, 2022 - Aug 23, 2023
Return:+72.40%
The most profitable trade made by Allan Shaw

Allan Shaw's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
Akari Therapeutics
Jan 02, 2015
Director
Uninformative Buy
$90.53K
Onconetix
Aug 23, 2022
Director
Informative Buy
296.36
$0.00
CalciMedica
Director
VVUSQ
Vivus
$747.51
List of latest transactions for each holding click on a transaction to see Allan Shaw's performance on stock

Allan Shaw insider profile FAQ

What is the percentage of profitable transactions made by Allan Shaw?
The percentage of profitable transactions made by Allan Shaw is 50%.
    What is the average return per transaction made by Allan Shaw?
    The average return per transaction made by Allan Shaw is 36.20%.
      What stocks does Allan Shaw hold?
      Allan Shaw holds: AKTX, ONCO, CALC, VVUSQ stocks.
        What was Allan Shaw’s latest transaction?
        Allan Shaw latest transaction was an Informative Buy of $296.36.
          What was Allan Shaw's most profitable transaction?
          Allan Shaw’s most profitable transaction was an Informative Sell of ONCO stock on August 23, 2022. The return on the trade was 72.40%.
            What is Allan Shaw's role in Akari Therapeutics?
            Allan Shaw's role in Akari Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.